Adlai acquiring ONCY? Adlai alone could provide a moon shot up:
https://www.oncolyticsbiotech.com/press-releases/detail/389/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd
Terms of The Agreement
Oncolytics will receive an upfront licensing fee and milestone payments to support the phase 3 registration study in metastatic breast cancer (mBC) of USD $21.2 million, and is eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercialization milestones. Oncolytics is also eligible to receive double digit royalty payments associated with the commercialization of REOLYSIN® for all indications, subject to regulatory approval. Included in the USD $21.2 million:
- Upfront payments of USD $5.3 million
- Two milestone payments totalling USD $8 million made up of two common share purchase warrants:
- One common share purchase warrant of USD $2 million whereby, upon exercise, Adlai may purchase Oncolytics' common shares priced at a 120% premium of the five-day weighted average closing price immediately preceding the exercise date. Oncolytics has the right to call this warrant when the first patient is enrolled in the phase 3 mBC study or six months after execution of The Agreement, whichever is later.
- One common share purchase warrant of USD $6 million whereby, upon exercise, Adlai may purchase Oncolytics' common shares priced at a 120% premium of the five-day weighted average closing price immediately preceding the exercise date. Oncolytics has the right to call this warrant upon the enrollment of the 50th patient in the phase 3 mBC study.
- USD $7.9 million based on certain regulatory advancements.
Oncolytics recently had a favorable End-of-Phase 2 Meeting with the United States Food and Drug Administration that outlined a single, 400-patient phase 3 study focused on HR+/HER2- patients. The Company expects to have formal guidance back from the European Medicines Agency (EMA) before the end of the year and to begin enrolling patients in its phase 3 study in mid-2018.
Adlai Nortye will be responsible for all clinical, regulatory and commercialization activities in its territories. Oncolytics maintains exclusive rights outside of these territories and will be responsible for all development outside of these territories.
https://www.oncolyticsbiotech.com/press-releases/detail/389/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd
Timing for licensing is difficult.
Oddly it appears cheaper to just buyout ONCY. Adlai could offer 200 millions USD and no can oppose it.
Could Adlai just take over ONCY now that their own research is impress with the data?
Why pay 86 million $ USD when you can buy it out for 200 million $ USD
The term of the agreement clearly demonstrate Adlai being interestered in become a major shareholder.
So, this gets interesting.